NCT02065011View on ClinicalTrials.gov

A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 12, 2013

Primary Completion Date

June 13, 2031

Study Completion Date

June 13, 2031

Conditions
Usher's Syndrome
Interventions
DRUG

Blood draw for the laboratory assessment

Trial Locations (2)

75012

Investigational Site Number : 250001, Paris

97239-3098

Oregon Health and Science University Site Number : 840001, Portland

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY